Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Oct;116(4):865-875.
doi: 10.1097/AOG.0b013e3181f20177.

Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial

Andrea S Lukes  1 , Keith A Moore, Ken N Muse, Janet K Gersten, Bryan R Hecht, Måns Edlund, Holly E Richter, Scott E Eder, George R Attia, Donald L Patrick, Arkady Rubin, Gary A Shangold
Affiliations
Clinical Trial

Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial

Andrea S Lukes et al. Obstet Gynecol. 2010 Oct.

Abstract

Objective: To assess the efficacy and safety of an oral formulation of tranexamic acid for the treatment of heavy menstrual bleeding.

Methods: Adult women with heavy menstrual bleeding (mean menstrual blood loss 80 mL or more per cycle) were enrolled in a double-blind, placebo-controlled study. After two pretreatment menstrual cycles, women were randomized to receive tranexamic acid 3.9 g/d or placebo for up to 5 days per menstrual cycle through six cycles. To meet the prespecified three-component primary efficacy end point, mean reduction in menstrual blood loss from baseline with tranexamic acid treatment needed to be 1) significantly greater than placebo, 2) greater than 50 mL, and 3) greater than a predetermined meaningful threshold (36 mL or higher). Health-related quality of life was measured using a validated patient-reported outcome instrument.

Results: Women who received tranexamic acid (n=115) met all three primary efficacy end points: first, a significantly greater reduction in menstrual blood loss of -69.6 mL (40.4%) compared with -12.6 mL (8.2%) in the 72 women who received placebo (P<.001); reduction of menstrual blood loss exceeding a prespecified 50 mL; and last, reduction of menstrual blood loss considered meaningful to women. Compared with women receiving placebo, women treated with tranexamic acid experienced significant improvements in limitations in social or leisure and physical activities, work inside and outside the home, and self-perceived menstrual blood loss (P<.01). The majority of adverse events were mild to moderate in severity, and the incidence of gastrointestinal adverse events was comparable with placebo.

Conclusion: In this study, a new oral tranexamic acid treatment was well tolerated and significantly improved both menstrual blood loss and health-related quality of life in women with heavy menstrual bleeding.

Clinical trial registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00386308.

Level of evidence: I.

PubMed Disclaimer

Comment in

References

    1. Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss: a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320–51.
    1. Rees M. Menorrhagia. Br Med J (Clin Res Ed) 1987;294:759–62.
    1. Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM. Determination of total menstrual blood loss. Fertil Steril 2001;76:125–31.
    1. Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract 1994;11:394–401.
    1. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007;10:183–94.

Publication types

Associated data